Immunomodulation: A new horizon for medicaltreatment of heart failure

This publication has 30 references indexed in Scilit:

• Vesnarinone inhibits induction of nitric oxide synthase in J774 macrophages and rat cardiac myocytes in culture
  Cardiovascular Research, 1995
• Inhibition of cytokine production by a new inotropic agent, vesnarinone, in human lymphocytes, T cell line, and monocytic cell line
  Life Sciences, 1994
• Increased circulating cytokines in patients with myocarditis and cardiomyopathy.
  Heart, 1994
• Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. Suppression of natural killer cell activity and tumor necrosis factor-alpha production.
  Journal of Clinical Investigation, 1994
• Negative Inotropic Effects of Cytokines on the Heart Mediated by Nitric Oxide
  Science, 1992
• A case of biopsy-proven myocarditis progressing to autopsy-proven dilated cardiomyopathy
  Clinical Cardiology, 1990
• A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure
  Cardiovascular Drugs and Therapy, 1990
• DETECTION OF COXSACKIE-B-VIRUS-SPECIFIC RNA SEQUENCES IN MYOCARDIAL BIOPSY SAMPLES FROM PATIENTS WITH MYOCARDITIS AND DILATED CARDIOMYOPATHY
  The Lancet, 1986
• Acute hemodynamic effects of a new inotropic agent, OPC-8212, on severe congestive heart failure
  Heart and Vessels, 1986
• Virological study of idiopathic cardiomyopathy. Serological study of virus antibodies and immunofluorescent study of myocardial biopsies.
  Japanese Circulation Journal, 1981